Spore-based probiotic composition for modulation of dermal and sub-dermal properties
The present invention relates to methods of modulating dermal and sub-dermal properties of a subject. The present invention relates to methods comprising administering to a subject a spore-based probiotic composition.
1. A method of modulating dermal and sub-dermal properties of a human subject in need thereof, comprising the steps of:
a. identifying the human subject in need of dermal or sub-dermal modulation;
b. administering to the human subject an effective amount of a spore-based probiotic composition comprising strains Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans (SC-208), Bacillus clausii (SC-109), and Bacillus licheniformis , each strain comprising Bacillus spores.
2. The method of claim 1 , wherein one or more of acetate, propionate, or butyrate is increased in the human gastro-intestinal tract.
3. The method of claim 2 , wherein the ratio of acetate to propionate or butyrate is substantially increased in the human gastro-intestinal tract.
4. The method of claim 1 , wherein the spore-based probiotic composition is administered in a daily dose of about 1×10 8 to about 1×10 12 Bacillus spores (CFUs).
5. The method of claim 4 , wherein the spore-based probiotic composition is administered in a daily dose of about 4×10 9 Bacillus spores (CFUs).
6. The method of claim 1 , wherein said modulated properties are one or more of increased skin hydration, reduced wrinkly appearance, reduced sebum content, reduced skin inflammation, beneficial changes in the lipidome on the skin, beneficial changes in the skin microbiota, and reduced the appearance and/or frequency of acne lesions or rosacea.
7. The method of claim 1 , wherein said administering step is by oral administration.
8. A method of reducing the appearance and/or frequency of acne lesions of a human subject in need thereof, comprising the steps of:
a. identifying the human subject in need of dermal or sub-dermal modulation;
b. administering to the human subject an effective amount of a spore-based probiotic composition comprising strains Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans (SC-208), Bacillus clausii (SC-109), and Bacillus licheniformis , each strain comprising Bacillus spores.
9. The method of claim 8 , wherein one or more of acetate, propionate, or butyrate is increased in the human gastro-intestinal tract.
10. The method of claim 9 , wherein the ratio of acetate to propionate or butyrate is substantially increased in the human gastro-intestinal tract.
11. The method of claim 8 , wherein the spore-based probiotic composition is administered in a daily dose of about 1×10 8 to about 1×10 12 Bacillus spores (CFUs).
12. The method of claim 11 , wherein the spore-based probiotic composition is administered in a daily dose of about 4×10 9 Bacillus spores (CFUs).
13. The method of claim 8 , wherein said administering step is by oral administration.
14. A spore-based probiotic composition comprising therapeutically effective amounts of the strains Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans (SC-208), Bacillus clausii (SC-109), and Bacillus licheniformis , each strain comprising Bacillus spores.
15. The composition of claim 14 , wherein said composition is a dietary supplement.
16. The composition of claim 14 , wherein said spores are microencapsulated.
17. The composition of claim 14 , further comprising endosomes.